AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | Human |
Product Type | Organoid + TIL |
Tissue | Adaptive |
Disease |
Applications
Colorectal cancer
Colorectal cancer organoids faithfully mimic patient tumors, aiding drug testing and personalized treatment strategies through biomarker identification and high-throughput screening in a realistic tumor microenvironment
Non-small cell lung cancer
Non-small cell lung cancer organoids mirror patient tumor diversity and genetics, providing a robust platform for detailed cancer research, including drug responses and personalized treatment exploration
Pancreatic cancer
Pancreatic cancer organoids replicate patient tumor complexity, informing drug responses, disease modeling, and biomarker discovery to advance personalized treatment strategies and research
Breast cancer
Patient-derived breast cancer organoids mimic tumor complexities, facilitating diverse drug testing and precision medicine research for personalized treatment strategies
Cholangiocarcinoma
Cholangiocarcinoma organoids aid in personalized treatment strategies by replicating patient tumor complexity and advancing research through biomarker identification and drug screening
Tumor-infiltrating lymphocytes (TILs) are immune cells in cancer tissues with the potential to either eliminate or aid in cancer growth.
Immunotherapeutics can reactivate exhausted TILs, allowing them to attack cancer cells.
Direct extraction and cultivation of TILs provide an evaluation solution for immunotherapeutics, and the extraction yield can predict their responsiveness, considering potential absence due to extraction yield or unique cancer characteristics.
Tumor-infiltrating lymphocytes (TIL) refer to lymphocytes that infiltrate tumors either intrinsically or extrinsically to eliminate tumors or help tumor growth.
Some TIL have antitumor reactivity that can eliminate tumor cells, but they often exist in an inhibited state.
Our company has developed conditions to extract and culture TIL from patients’ tumors.
During TIL culture, the number of cytotoxic T cells increased, and the expression levels of various immune checkpoint molecules allowed us to check the status of TIL.
Overall efficacy (Death cells)
When evaluating the efficacy of atezolizumab in co-culture conditions with tumor organoids and tumor-infiltrating lymphocytes or tumor organoids and T cells derived from PBMCs, higher tumor organoid killing was observed in conditions without co-culture with tumor-infiltrating lymphocytes or T cells.
The method of evaluating efficacy by treating a specific mixture of tumor organoids and tumor-infiltrating lymphocytes with anticancer drugs is still at the research level globally, and our company uniquely holds patents and commercialization services related to this.
Make your research shine brighter through the only service of its kind in the world.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
